BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...

A woman suffering debilitating symptoms is crediting WVU Medicine for giving her her life back after finally receiving a ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

At only 27 years old, Daniela Powers felt like she was dying. What began as unexplained rashes exploded into a debilitating ...

Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share ...

Haemonetics Corporation announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations ...

The discontinued programmes are headed by NTLA-3001, an in vivo CRISPR drug developed as a one-shot treatment for lung disease associated ... HAELO for NTLA-2002 in HAE and the MAGNITUDE and ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Worried there are no great-value ASX shares left to buy? Our Foolish writers reckon these five are worth a good look!

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

This week's latest OTT releases promise an exciting mix of suspense and drama, delivering gripping storylines, emotional ...

Korea is expected to spend around 6 trillion won ($4.6 billion) this year on treating diseases related to aging such as ...